Novo Nordisk semaglutide phase 3 trial for MASH meets primary endpoints

by


Liver damage such as Fatty liver, Fibrosis, Cirrhosis, and Liver cancer. 3d illustration

Mohammed Haneefa Nizamudeen

  • A phase 3 trial examining Novo Nordisk’s (NVO) GLP-1 medicine semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) met its primary endpoints.
  • Those endpoints were significant improvement in liver fibrosis with no worsening of steatohepatitis, and no worsening of liver


Leave a Comment